www.alnylam.com Open in urlscan Pro
2620:12a:8000::253  Public Scan

Form analysis
4 forms found in the DOM

GET /search-results

<form action="/search-results" method="GET">
  <div class="search-input input-group hide">
    <input type="text" name="keyword" placeholder="Type something">
    <button type="submit">search</button>
  </div>
  <button type="button" class="search-open-btn"><img src="/modules/custom/alnylam_search/images/search-icon.png" loading="eager"></button>
  <button type="button" class="search-close-btn hide"><img src="/modules/custom/alnylam_search/images/search-close-icon.png" loading="eager"></button>
</form>

GET /search-content

<form action="/search-content" method="get" id="views-exposed-form-search-content-page-1" accept-charset="UTF-8">
  <div class="form--inline form-inline clearfix">
    <div class="form-item js-form-item form-type-textfield js-form-type-textfield form-item-keyword js-form-item-keyword form-no-label form-group">
      <input placeholder="Type something" data-drupal-selector="edit-keyword" class="form-text form-control" type="text" id="edit-keyword" name="keyword" value="" size="30" maxlength="128">
    </div>
    <div class="form-item js-form-item form-type-select js-form-type-select form-item-sort-by js-form-item-sort-by form-group">
      <label for="edit-sort-by" class="control-label">Sort by</label>
      <div class="select-wrapper"><select data-drupal-selector="edit-sort-by" class="form-select form-control" id="edit-sort-by" name="sort_by">
          <option value="sort_by" selected="selected">Sort By:</option>
        </select></div>
    </div>
    <div class="form-item js-form-item form-type-select js-form-type-select form-item-sort-order js-form-item-sort-order form-group">
      <label for="edit-sort-order" class="control-label">Order</label>
      <div class="select-wrapper"><select data-drupal-selector="edit-sort-order" class="form-select form-control" id="edit-sort-order" name="sort_order">
          <option value="ASC">Sort by: Most Recent</option>
          <option value="DESC" selected="selected">Sort by: Oldest</option>
        </select></div>
    </div>
    <div data-drupal-selector="edit-actions" class="form-actions form-group js-form-wrapper form-wrapper" id="edit-actions"><button data-drupal-selector="edit-submit-search-content"
        class="button js-form-submit form-submit btn-primary btn icon-before" type="submit" id="edit-submit-search-content" value="Search" name=""><span class="icon glyphicon glyphicon-search" aria-hidden="true"></span> Search</button></div>
  </div>
</form>

GET /search-results

<form action="/search-results" method="GET">
  <div class="search-input input-group hide">
    <input type="text" name="keyword" placeholder="Type something">
    <button type="submit">search</button>
  </div>
  <button type="button" class="search-open-btn"><img src="/modules/custom/alnylam_search/images/search-icon.png" loading="eager"></button>
  <button type="button" class="search-close-btn hide"><img src="/modules/custom/alnylam_search/images/search-close-icon.png" loading="eager"></button>
</form>

GET /search-content

<form action="/search-content" method="get" id="views-exposed-form-search-content-page-1" accept-charset="UTF-8">
  <div class="form--inline form-inline clearfix">
    <div class="form-item js-form-item form-type-textfield js-form-type-textfield form-item-keyword js-form-item-keyword form-no-label form-group">
      <input placeholder="Type something" data-drupal-selector="edit-keyword" class="form-text form-control" type="text" id="edit-keyword--2" name="keyword" value="" size="30" maxlength="128">
    </div>
    <div class="form-item js-form-item form-type-select js-form-type-select form-item-sort-by js-form-item-sort-by form-group">
      <label for="edit-sort-by--2" class="control-label">Sort by</label>
      <div class="select-wrapper"><select data-drupal-selector="edit-sort-by" class="form-select form-control" id="edit-sort-by--2" name="sort_by">
          <option value="sort_by" selected="selected">Sort By:</option>
        </select></div>
    </div>
    <div class="form-item js-form-item form-type-select js-form-type-select form-item-sort-order js-form-item-sort-order form-group">
      <label for="edit-sort-order--2" class="control-label">Order</label>
      <div class="select-wrapper"><select data-drupal-selector="edit-sort-order" class="form-select form-control" id="edit-sort-order--2" name="sort_order">
          <option value="ASC">Sort by: Most Recent</option>
          <option value="DESC" selected="selected">Sort by: Oldest</option>
        </select></div>
    </div>
    <div data-drupal-selector="edit-actions" class="form-actions form-group js-form-wrapper form-wrapper" id="edit-actions--2"><button data-drupal-selector="edit-submit-search-content-2"
        class="button js-form-submit form-submit btn-primary btn icon-before" type="submit" id="edit-submit-search-content--2" value="Search" name=""><span class="icon glyphicon glyphicon-search" aria-hidden="true"></span> Search</button></div>
  </div>
</form>

Text Content

Skip to main content
 * Our Company »
   * About Alnylam
   * Leadership
   * Diversity, Equity & Inclusion
   * Patient Access Philosophy
   * Corporate Responsibility
   * Transparency
   * Grants & Giving
   * Investigator Initiated Studies (IIS)
 * Our Science »
   * The Science of RNAi
   * Delivery Platforms
   * Therapeutic Areas
   * Pipeline
   * Clinical Trials
   * Scientific Advisory Board
   * Intellectual Property
   * Capella (Scientific Presentations)
 * Our Products »
   * Product Listing
 * Our News »
   * Newsroom
   * Press Releases
   * Capella (Scientific Presentations)
   * Media Kit
 * Investors »
   * For Investors
   * Stock Information
   * Investors Toolkit
   * Events & Presentations
   * Financial Information
   * SEC Filings
   * Corporate Governance
   * Analyst Coverage
   * Fundamentals
   * Ownership Profile
   * Annual Meetings
   * Press Releases
   * Capella (Scientific Presentations)
   * FAQs
 * Medical Professionals »
   * For Medical Professionals
   * Genetic Testing & Counseling
   * Early Access Program
   * Medical Publication Support
   * Investigator Initiated Studies (IIS)
 * Patients »
   * For Patients
   * Amyloidosis
   * Acute Hepatic Porphyria
   * Primary Hyperoxaluria
   * Patient Services
   * Genetic Testing and Counseling
   * Patient Advocacy
 * Job Seekers »
   * Careers
   * Working at Alnylam
   * Who We Are
   * Career Opportunities
   * Search Jobs
   * Diversity, Equity & Inclusion
 * Quick Links »
   * Clinical Trials
   * Corporate Responsibility
   * Diversity, Equity & Inclusion
   * Press Releases
   * Capella (Scientific Presentations)
   * Medical Resources (RNAi Science)
   * Contact Us


search
Sort by
Sort By:
Order
Sort by: Most RecentSort by: Oldest
Search
language
Global
English
Austria
Deutsch
Japan
日本語
Belgium
Nederlands
Français
Luxembourg
Français
Deutsch
Brazil
Português
Netherlands
Nederlands
Canada
Français
English
Portugal
Português
Czech Republic
Čeština
Spain
Español
Denmark
Dansk
Sweden
Svenska
France
Français
Switzerland
Français
Deutsch
Italiano
Germany
Deutsch
Taiwan
繁體中文
Ireland
English
United Kingdom
English
Italy
Italiano
 * Investors »
   * For Investors
   * Stock Information
   * Investors Toolkit
   * Events & Presentations
   * Financial Information
   * SEC Filings
   * Corporate Governance
   * Analyst Coverage
   * Fundamentals
   * Ownership Profile
   * Annual Meetings
   * Press Releases
   * Capella (Scientific Presentations)
   * FAQs
 * Medical Professionals »
   * For Medical Professionals
   * Genetic Testing & Counseling
   * Early Access Program
   * Medical Publication Support
   * Investigator Initiated Studies (IIS)
 * Patients »
   * For Patients
   * Amyloidosis
   * Acute Hepatic Porphyria
   * Primary Hyperoxaluria
   * Patient Services
   * Genetic Testing and Counseling
   * Patient Advocacy
 * Job Seekers »
   * Careers
   * Working at Alnylam
   * Who We Are
   * Career Opportunities
   * Search Jobs
   * Diversity, Equity & Inclusion
 * Quick Links »
   * Clinical Trials
   * Corporate Responsibility
   * Diversity, Equity & Inclusion
   * Press Releases
   * Capella (Scientific Presentations)
   * Medical Resources (RNAi Science)
   * Contact Us
 * Follow Us »
   * Youtube
   * Facebook
   * X
   * LinkedIn
   * Instagram
   * Sign Up

language
 * Our Company »
   * About Alnylam
   * Leadership
   * Diversity, Equity & Inclusion
   * Patient Access Philosophy
   * Corporate Responsibility
   * Transparency
   * Grants & Giving
   * Investigator Initiated Studies (IIS)
 * Our Science »
   * The Science of RNAi
   * Delivery Platforms
   * Therapeutic Areas
   * Pipeline
   * Clinical Trials
   * Scientific Advisory Board
   * Intellectual Property
   * Capella (Scientific Presentations)
 * Our Products »
   * Product Listing
 * Our News »
   * Newsroom
   * Press Releases
   * Capella (Scientific Presentations)
   * Media Kit

search
Sort by
Sort By:
Order
Sort by: Most RecentSort by: Oldest
Search
Global
English
Austria
Deutsch
Japan
日本語
Belgium
Nederlands
Français
Luxembourg
Français
Deutsch
Brazil
Português
Netherlands
Nederlands
Canada
Français
English
Portugal
Português
Czech Republic
Čeština
Spain
Español
Denmark
Dansk
Sweden
Svenska
France
Français
Switzerland
Français
Deutsch
Italiano
Germany
Deutsch
Taiwan
繁體中文
Ireland
English
United Kingdom
English
Italy
Italiano


DISRUPTING DISEASE™

Alnylam’s RNAi therapeutics silence the genes that cause or contribute to
disease

Learn How ›


PIONEERED HERE

Alnylam’s pioneering work in RNAi has created this innovative new class of
medicines

Learn How ›


PEOPLE FIRST

Whether they’re patients, or members of our communities, people are at the
center of all we do

Learn More ›


BROAD IMPACT

Moving beyond just rare diseases, we aim to improve the lives of millions

OUR PIPELINE ›
prev
next


THE LEADING RNAI THERAPEUTICS COMPANY

Alnylam’s pioneering science has yielded the critical breakthroughs and
innovations that have made RNA interference (RNAi)-based medicines a reality.

We ushered in the first phase of the RNAi RevolutionTM by developing the first
five approved RNAi therapeutics. Now, we’re pioneering what’s next, working to
bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both
rare and which impact millions of people around the world.

MORE ABOUT ALNYLAM ›


SILENCING GENES TO DISRUPT DISEASE



RNA interference (RNAi) is a naturally occurring process already at work inside
your body which regulates how genes make new proteins. Proteins play a critical
role in almost everything your body does, but sometimes, they can cause or
contribute to disease. Our medicines leverage the RNAi process to prevent
specific proteins from being made, disrupting disease at its source.

We believe that this revolutionary approach can be used to silence virtually any
gene in the genome… meaning that the diseases we’re treating today are just the
beginning of what’s possible.

MORE ABOUT RNAi ›


OUR PIPELINE

Our robust pipeline of investigational RNAi therapeutics is currently focused on
diseases with high unmet medical need, including transthyretin amyloidosis, rare
diseases, cardiovascular diseases, metabolic diseases, and neurological
diseases. Additionally, we will always follow the science and are continually
looking for new disease targets that may benefit from our RNAi technology.

 

Genetic Medicines

 

Cardio-Metabolic Diseases

 

Infectious Diseases

 

Central Nervous System & Ocular Diseases

EXPLORE OUR PIPELINE ›


PATIENTS COME FIRST

While we’re driven by science, we’re motivated by people because for us, this is
personal. Whether we're working to develop the first treatment for a disease or
a better one, patients are the center of all we do. They are the reason we come
to work every day, and their stories inspire us to continue to innovate by
pushing the science of RNAi therapeutics forward.

LEARN MORE ›

My body started to warn me that something was wrong. That I had a problem… My
father passed away 40 years ago; after I received my diagnosis, we believe what
he really had was hATTR amyloidosis like me.

-Chen, living with hATTR amyloidosis

 



ALNYLAM NEWS

VISIT THE NEWSROOM ›

HELIOS-B PHASE 3 TOPLINE RESULTS

Alnylam announces positive topline results from the Phase 3 clinical trial of
vutrisiran
view article ›

OUR COMMITMENT TO PATIENT ACCESS

We’ve published our latest Patient Access Philosophy & Progress fact sheet
view article ›

ALNYLAM RANKED #3 ON LINKEDIN'S LIST OF TOP MIDSIZE COMPANIES

We are honored to be recognized for our commitment to employee career growth.
view article ›

CORPORATE RESPONSIBILITY AT ALNYLAM

We’ve published our fourth annual Corporate Responsibility Report
view article ›

ALNYLAM IS RECOGNIZED AS A TOP PLACE TO WORK FOR THE 10TH YEAR IN A ROW

We’re proud to consecutively top The Boston Globe’s Massachusetts Largest
Employer list
view article ›

ALNYLAM NAMED A TOP SCIENCE EMPLOYER BY SCIENCE MAGAZINE

This is our 6th consecutive year on the Science Magazine Top Employer list
view article ›

ALNYLAM RECOGNIZED AS A BEST WORKPLACE FOR INNOVATORS

2024 marks our fourth consecutive year on the Fast Company list
view article ›

HELIOS-B PHASE 3 TOPLINE RESULTS

Alnylam announces positive topline results from the Phase 3 clinical trial of
vutrisiran
view article ›

OUR COMMITMENT TO PATIENT ACCESS

We’ve published our latest Patient Access Philosophy & Progress fact sheet
view article ›

ALNYLAM RANKED #3 ON LINKEDIN'S LIST OF TOP MIDSIZE COMPANIES

We are honored to be recognized for our commitment to employee career growth.
view article ›

CORPORATE RESPONSIBILITY AT ALNYLAM

We’ve published our fourth annual Corporate Responsibility Report
view article ›

ALNYLAM IS RECOGNIZED AS A TOP PLACE TO WORK FOR THE 10TH YEAR IN A ROW

We’re proud to consecutively top The Boston Globe’s Massachusetts Largest
Employer list
view article ›

ALNYLAM NAMED A TOP SCIENCE EMPLOYER BY SCIENCE MAGAZINE

This is our 6th consecutive year on the Science Magazine Top Employer list
view article ›

ALNYLAM RECOGNIZED AS A BEST WORKPLACE FOR INNOVATORS

2024 marks our fourth consecutive year on the Fast Company list
view article ›

HELIOS-B PHASE 3 TOPLINE RESULTS

Alnylam announces positive topline results from the Phase 3 clinical trial of
vutrisiran
view article ›

OUR COMMITMENT TO PATIENT ACCESS

We’ve published our latest Patient Access Philosophy & Progress fact sheet
view article ›

ALNYLAM RANKED #3 ON LINKEDIN'S LIST OF TOP MIDSIZE COMPANIES

We are honored to be recognized for our commitment to employee career growth.
view article ›

CORPORATE RESPONSIBILITY AT ALNYLAM

We’ve published our fourth annual Corporate Responsibility Report
view article ›
 * 1
 * 2
 * 3
 * 4
 * 5
 * 6
 * 7

Previous Next


OUR COMMITMENTS

Corporate Responsibility

Our Inclusive Culture


ACCEPTING CHALLENGES TO IMPROVE THE HEALTH OF HUMANITY

We believe that our actions as a company can be a force for good in the world
both inside our labs and beyond. We aspire to make a positive impact in the
world beyond the medicines we make through focusing on patients, science,
employees, communities, our planet and corporate governance.

LEARN MORE ›





WE'RE DRIVEN TO CHANGE THE WORLD

We are proud of the award-winning, open, dynamic, and diverse culture we have
built. Here, our employees feel included, supported, and heard. We are committed
to building a work environment with a shared mission and values, where all
employees are enabled to achieve their full potential.

LEARN MORE ›





THIS IS YOUR MOMENT TO JOIN US

We're 2,000+ smart, passionate, "change the world" kind of people who believe
deeply in the power and potential of our technology and what we're building as a
company. If you are looking for a mission, colleagues that inspire, and a
company that recognizes and rewards both group and individual contributions,
perhaps this is your moment to join us.

JOIN US ›
You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content
on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site


FOLLOW US

Visit our social channels to learn more about the innovative work we are doing
at Alnylam.




FOOTER FIRST

 * Our Company
 * Our Science
 * Our Products
 * Our News


FOOTER MENU

 * Privacy Policy
 * Site Map
 * Legal Notice
 * Sign Up For Updates


FOOTER SECOND

 * Investors
 * Medical Professionals
 * Patients
 * Job Seekers


FOOTER THIRD MENU

 * Clinical Trials
 * Corporate Responsibility
 * Diversity, Equity & Inclusion
 * Press Releases
 * Capella
 * Medical Resources (RNAi Science)
 * Contact Us
 * Sign Up For Updates


FOOTER FOUTH MENU

 * Privacy Policy
 * Media Kit
 * Legal Notice
 * Site Map

Copyright © 2024 Alnylam Pharmaceuticals, Inc. — All Rights Reserved







USE OF COOKIES

We use our own and third-party cookies and other technologies (“cookies”) to
enhance your website experience. Beside the strictly necessary cookies used to
run the website, we would like to use optional cookies to learn more regarding
the use of the website and their performance, to improve your user experience
and include additional functionalities, for marketing purposes to provide you
with relevant content, and to enable you to share content in social media
platforms. You can customize your choices in the section “Adjust Settings”. For
further information, please check our Cookie Policy. To learn more about our
company policies, please visit our policies page.
Adjust Settings Reject All Accept All



PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
Allow All


MANAGE CONSENT PREFERENCES

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalization. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies than some
or all of these services may not function properly.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

STRICTLY NECESSARY COOKIES

Always Active
Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous, and we
share this data with third party analytics companies who provide services on our
behalf. If you do not allow these cookies we will not know when you have visited
our site, and will not be able to monitor its performance.

Reject All Accept Selection

Back Button

Back


PERFORMANCE COOKIES



Vendor Search Search Icon Filter Icon


Clear Filters

Information storage and access
Apply
Consent Leg.Interest

All Consent Allowed

Select All Vendors
Select All Vendors
Select All Hosts

Reject All Accept Selection